Personalized Osilodrostat Therapy for Individuals with ACTH-Dependent Cushing’s Syndrome: Insights from Real-World Data
Clinical Scorecard: Personalized Osilodrostat Therapy for Individuals with ACTH-Dependent Cushing’s Syndrome: Insights from Real-World Data
At a Glance
| Category | Detail |
|---|
| Condition | ACTH-Dependent Cushing’s Syndrome |
| Key Mechanisms | Osilodrostat is an 11β-hydroxylase inhibitor that reduces cortisol production. |
| Target Population | Adults with ACTH-dependent Cushing’s syndrome, including Cushing’s disease and ectopic Cushing’s syndrome. |
| Care Setting | Tertiary referral center specializing in pituitary diseases and hypercortisolism. |
Key Highlights
- 92% of patients achieved a therapeutic effect at a median dose of 5 mg/day within 14 days.
- Morning cortisol normalized in 92% of cases and urinary free cortisol in 75%.
- Median clinical score decreased from 9 to 4, with muscle strength improvement from 50% to 75% of normal.
- Systolic/diastolic blood pressure decreased significantly, allowing reduction of antihypertensive therapy in most patients.
- Adverse events were mild to moderate, with fatigue and nausea reported in 34.6% of patients.
Guideline-Based Recommendations
Diagnosis
- Diagnosis of ACTH-dependent Cushing’s syndrome should include assessment of cortisol levels and imaging studies.
Management
- Osilodrostat is recommended as a second-line pharmacological therapy for patients with ACTH-dependent Cushing’s syndrome.
Monitoring & Follow-up
- Regular monitoring of cortisol levels and clinical symptoms is essential during osilodrostat therapy.
Risks
- Potential adverse events include fatigue, nausea, adrenal insufficiency, and dizziness.
Patient & Prescribing Data
26 adults with ACTH-dependent Cushing’s syndrome treated with osilodrostat.
Osilodrostat was introduced as first-line therapy in 12 patients, with a titration regimen used in 21 patients.
Clinical Best Practices
- Individualized dosing and titration of osilodrostat based on patient response.
- Close monitoring of blood pressure and glucose levels during treatment.
Related Resources & Content
